本文選題：抗腫瘤輔助用藥 + 分析��； 參考：《中國藥房》2015年11期

【摘要】：目的:促進(jìn)抗腫瘤輔助用藥的安全、合理和經(jīng)濟(jì)使用。方法:回顧性分析我院2013年1-6月(干預(yù)前)和7-12月(干預(yù)后)抗腫瘤輔助用藥應(yīng)用情況及評價(jià)干預(yù)效果。結(jié)果:通過技術(shù)干預(yù)、行政干預(yù)、信息干預(yù)等措施,不合理使用抗腫瘤輔助用藥得到有效改善,抗腫瘤輔助用藥占藥品總收入的比例,干預(yù)前為59.07%,干預(yù)后為47.17%,下降11.90%。結(jié)論:腫瘤治療中輔助用藥目前尚缺少客觀和系統(tǒng)的評價(jià)依據(jù),通過臨床查找循證證據(jù),客觀評價(jià)用藥合理性,逐步規(guī)范輔助用藥行為,可以規(guī)避用藥風(fēng)險(xiǎn)。
[Abstract]:Objective: to promote the safety, rational and economical use of antitumor adjuvant drugs. Methods: the application of antitumor adjuvant drugs in our hospital from January to June 2013 (before intervention) and from July to December (after intervention) were analyzed retrospectively and the effect of intervention was evaluated. Results: through technical intervention, administrative intervention, information intervention and other measures, the irrational use of anti-tumor adjuvant drugs was effectively improved. The proportion of anti-tumor adjuvant drugs in the total income of drugs was 59.07 before intervention, 47.17 after intervention, and decreased by 11.90. Conclusion: there is no objective and systematic evaluation basis for adjuvant drug use in tumor therapy at present. The risk of drug use can be avoided by looking up evidence based on evidence objectively evaluating the rationality of drug use and standardizing the behavior of adjuvant drug use step by step.
【作者單位】： 南通市腫瘤醫(yī)院藥劑科;
【分類號】：R95

【參考文獻(xiàn)】

相關(guān)期刊論文 前7條

1 宋利瓊;張昌菊;;莪術(shù)油聯(lián)合干擾素對小鼠宮頸癌端粒酶活性和細(xì)胞凋亡的影響[J];上海中醫(yī)藥雜志;2006年07期

2 文柳靜;;我院門診實(shí)施限制化療輔助用藥措施的相關(guān)分析[J];西北藥學(xué)雜志;2009年06期

3 孫紅梅;楊瑞雪;王敬梅;;綜合性醫(yī)院2001-2007年藥品比例變動趨勢研究[J];中國醫(yī)療前沿;2009年04期

4 郭s罾，

本文編號：1791131